Moreover, by alleviating tumor hypoxia, IMN reduced the expression of CD39 and CD73 on tumor cells, thereby decreasing eATP degradation and the immunosuppressive effects of eADO and Treg cells. The gene discussed is NT5E; the disease is neoplasm.